In the article we will look at the instructions for use and analogues for the drug “Jess”.
Today, oral contraception is considered the most effective way to protect against unwanted pregnancy. However, it has numerous disadvantages, which is why many women are in no hurry to give them preference. The modern contraceptive "Jess" combines ease of use and a minimal list of adverse reactions. The contraceptive drug "Jess" is a new generation oral monophasic contraceptive.
You will be interested in: “De-Nol”: reviews, instructions for use and composition
The mechanism of action of these contraceptive pills is similar to that of other oral contraceptives, but the formula of this medication is somewhat improved and improved. This is due to the presence in their composition of drospirenone, which is a fourth-generation progestogen, the effect of which on a woman’s body is as close as possible to natural progesterone. Drospirenone is able to block fluid and sodium retention in the body that is caused by estrogens. Against this background, as a result of taking other oral contraceptives, women experience negative side effects in the form of weight gain and swelling, which makes this medication very well tolerated.
You might be interested in: Infectious disease doctor: what does he treat, what diseases does he diagnose, when to see an infectious disease doctor?
In addition, drospirenone has a positive effect on the functioning of hormones in the premenstrual period, alleviating a woman’s condition in case of severe forms of PMS (reduces the intensity and frequency of psycho-emotional disorders, headaches, engorgement and inflammation of the mammary glands).
It is quite possible to find analogs in composition and cheaper than “Jess” on sale. Oral contraceptive pills "Jess" contain a minimal amount of estrogen, in comparison with other drugs of similar action - 20 mg, and this indicates the safety of this drug. Microdosing of hormones has a gentle effect on the female body, reducing the development of all kinds of complications and adverse reactions. The main indications for the use of this pharmaceutical product are contraception, as well as the treatment of acne and severe forms of premenstrual syndrome. Analogs of "Jess" are also prescribed for these purposes.
Positive properties of the drug "Jess"
You may be interested in: Probing of the lacrimal canal: indications for the procedure, consequences, reviews
Women who regularly take the medication observe a stabilization of the menstrual cycle, which becomes more regular, and the menstruation itself is more painful, the intensity of bleeding decreases, which prevents the occurrence of iron deficiency anemia. In addition, regular use of this medication reduces the risk of developing inflammatory pathologies in the female genital area. The medication also significantly reduces the discomfort that occurs before the onset of menstruation and in the middle of the cycle.
It should be noted that, according to epidemiological studies, combined oral contraceptive drugs, including all analogues of Jess tablets, reduce the likelihood of developing endometrial, ovarian and other cancers of the female organs.
In addition, due to its high antiandrogenic activity, the drug provides a therapeutic effect for certain skin diseases (acne), normalizes the condition of nails, and reduces oily hair and skin. Many women experience breast enlargement while using Jess. Also, this contraceptive helps slow down the development of osteoporosis and is an effective preventative against ectopic pregnancy. But the main thing is that this medication provides a persistent contraceptive effect, in which pregnancy can occur only if the norms for taking the drug are violated or if you refuse it. It should be noted that this remedy for unwanted pregnancy does not protect against sexually transmitted infections and STDs, therefore, if there are doubts about the sexual partner, you must additionally use barrier-type contraception.
Analogues of the Jess contraceptive should be selected by a doctor.
Mode of use
Each pack of contraceptive pills contains 28 tablets, 24 of which provide a contraceptive effect, and the remaining 4 have a placebo effect, that is, they do not have medicinal properties and are used as a means, the therapeutic effect of which is based on the woman’s belief in the effectiveness of the medicine. This provides an opportunity to maximize the effectiveness of the drug and prevent skipping tablets or starting a new package. The tablets should be taken daily, at the same time, and there is no need to take breaks between packs. Menstruation usually begins on the second or third day of taking the “placebo pill” and can last even after starting a new pack of medication.
You may be interested in: HLA typing and its role in infertility
Start of reception
If a woman has not taken any oral hormonal contraceptives in the previous month, then this drug should be started on the first day of menstrual bleeding. However, it is also allowed to take pills from the second to the fifth day of the cycle, only in this case you need to use some additional methods of contraception (for example, barrier) during the first seven days of using the medication.
When switching to this drug from other oral combined contraceptives, taking “Jess” must begin the day after the last active tablet from the package of the previous medication, no later than the next day after the usual seven-day break (in cases where there are 21 tablets in the pack), or after use the last inactive tablet (in cases where 28 tablets in the package are active).
When switching from a contraceptive patch or vaginal ring, it is recommended to start taking this drug on the day of such contraceptives, no later than the date when the new ring should be inserted or a new patch should be applied. It is allowed to switch from the mini-pill to the use of the drug “Jess” on any day without interruptions, and from a hormonal implant or intrauterine contraception with gestagen on the day of removal. Switching from contraceptive injections to the drug is carried out on the day of the next injection. In all cases, you should use barrier contraception (condoms) during the first week of taking these pills.
After an abortion, you can start drinking Jess contraceptives immediately, and additional contraception is not required. If this medication causes severe stomach disturbances (vomiting), you should proceed in the same way as if you missed a pill, plus additional means of protection should be used during sexual intercourse.
If you need to change the onset of menstruation, you need to continue taking tablets from the next pack, while skipping the placebo from the current pack of the drug. In this case, the cycle can be extended for the desired period until the active tablets from the second package run out. Against this background, a woman may experience breakthrough uterine bleeding or spotting. Regular use of Jess oral contraceptives is resumed after taking placebo tablets.
Jess Plus, 28 pcs., film-coated tablets
If any of the conditions, diseases and risk factors listed below currently exist, the potential risks and expected benefits of using Jess®Plus should be carefully weighed in each individual case and discussed with the woman before she decides to start taking of this drug.
Violations by the SSS
The results of epidemiological studies indicate a relationship between the use of COCs and an increased incidence of venous and arterial thrombosis and thromboembolism (such as DVT, PE, myocardial infarction, cerebrovascular disorders) when taking COCs. These diseases are rare.
The risk of developing VTE is greatest in the first year of taking COCs. An increased risk is present after initial use of a COC or resumption of use of the same or a different COC (after a dosing interval of 4 weeks or more). Data from a large prospective study involving 3 groups of patients indicate that this increased risk is predominantly present during the first 3 months.
The overall risk of developing VTE in women taking low-dose COCs (ethinyl estradiol <0.05 mg) is 2-3 times higher than in non-pregnant patients not taking COCs, however, this risk remains lower than the risk development of VTE during pregnancy and childbirth.
VTE can be life-threatening or fatal (in 1–2% of cases).
VTE, manifested as DVT or PE, can occur with all COCs.
It is extremely rare when using COCs that thrombosis of other blood vessels occurs, such as hepatic, mesenteric, renal, cerebral veins and arteries or retinal vessels.
Symptoms of DVT:
unilateral swelling of the lower limb or along a vein in the lower limb, pain or discomfort in the lower limb only in an upright position or when walking, local increase in temperature in the affected lower limb, redness or discoloration of the skin on the lower limb.
Symptoms of pulmonary embolism:
difficulty or rapid breathing; sudden cough, incl. with hemoptysis; sharp pain in the chest, which may intensify with deep inspiration; sense of anxiety; severe dizziness; fast or irregular heartbeat. Some of these symptoms (eg, shortness of breath, cough) are nonspecific and may be misinterpreted as signs of other more or less severe conditions (eg, respiratory tract infection).
Arterial thromboembolism can lead to stroke, vascular occlusion, or myocardial infarction.
Symptoms of a stroke:
sudden weakness or loss of sensation in the face, limbs, especially on one side of the body, sudden confusion, problems with speech and understanding; sudden unilateral or bilateral vision loss; sudden disturbance in gait, dizziness, loss of balance or coordination; sudden, severe or prolonged headache for no apparent reason; loss of consciousness or fainting with or without an epileptic seizure.
Other signs of vascular occlusion:
sudden pain, swelling and slight blueness of the limbs, acute abdomen.
Symptoms of myocardial infarction:
pain, discomfort, pressure, heaviness, a feeling of compression or fullness in the chest or behind the sternum, radiating to the back, jaw, left upper limb, epigastric region; cold sweat, nausea, vomiting or dizziness, severe weakness, anxiety or shortness of breath; fast or irregular heartbeat.
Arterial thromboembolism can be life-threatening or fatal.
In women with a combination of several risk factors or high severity of one of them (including complicated heart valve diseases, uncontrolled arterial hypertension, extensive surgical interventions with prolonged immobilization), the possibility of their mutual reinforcement should be considered. In such cases, the total value of the existing risk factors increases. In this case, taking Jess® Plus is contraindicated (see “Contraindications”).
The risk of developing thrombosis (venous and/or arterial), thromboembolism or cerebrovascular disorders increases:
- with age;
- in smokers (with an increase in the number of cigarettes or an increase in age, the risk increases, especially in women over 35 years old);
in the presence of:
— obesity (BMI >30 kg/m2);
- family history (including venous or arterial thromboembolism ever in close relatives or parents under the age of 50 years). In the case of a hereditary or acquired predisposition, the woman should be examined by an appropriate specialist to decide on the possibility of taking the drug Jess® Plus;
- prolonged immobilization, extensive surgery, any operation on the lower extremities or major trauma. In these situations, it is necessary to stop taking the drug Jess® Plus (in the case of a planned operation, at least 4 weeks before it) and not to resume taking it for 2 weeks after the end of immobilization. Temporary immobilization (eg, air travel lasting more than 4 hours) may also be a risk factor for the development of VTE, especially in the presence of other risk factors;
- dislipoproteinemia;
- arterial hypertension;
- migraine;
— diseases of the heart valves;
- atrial fibrillation.
The use of any combined hormonal contraceptives increases the risk of developing VTE. The use of drugs containing levonorgestrel, norgestimate or norethisterone carries the lowest risk of developing VTE. The use of other drugs, such as Jess® Plus, can lead to a twofold increase in risk. The choice to use a COC with a higher risk of developing VTE can only be made after consultation with the patient to ensure that she fully understands the risk of VTE associated with the use of Jess® Plus, the effect of the drug on her existing risk factors and that The risk of developing VTE is greatest during the first year of using the drug. According to some data, an increased risk is observed when COC use is resumed after a break of 4 weeks or more.
Approximately 9–12 out of 10,000 women taking COCs containing drospirenone may develop VTE within a year, compared with about 6 in 10,000 women for COCs containing levonorgestrel.
The possible role of varicose veins and superficial thrombophlebitis in the development of VTE remains controversial.
The increased risk of thromboembolism in the postpartum period should be taken into account.
Peripheral circulatory disorders may also occur in diabetes mellitus, SLE, hemolytic uremic syndrome, chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis) and SCD.
An increase in the frequency and severity of migraine during use of the drug Jess®Plus (which may precede cerebrovascular disorders) is grounds for immediate discontinuation of the drug.
Biochemical indicators indicating a hereditary or acquired predisposition to venous or arterial thrombosis include: resistance to activated protein C, hyperhomocysteinemia, antithrombin III deficiency, protein C deficiency, protein S deficiency, antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant).
When assessing the risk-benefit ratio, it should be taken into account that adequate treatment of the relevant condition can reduce the associated risk of thrombosis. It should also be taken into account that the risk of developing thrombosis and thromboembolism during pregnancy is higher than when taking low-dose oral contraceptives (ethinyl estradiol - <0.05 mg).
Tumors
The most significant risk factor for developing cervical cancer is persistent human papillomavirus infection. There are reports of a slight increase in the risk of developing cervical cancer with long-term use of COCs. However, the connection with taking COCs has not been proven. The possibility of the relationship of these data with screening for cervical diseases and with characteristics of sexual behavior (less frequent use of barrier methods of contraception) is discussed.
A meta-analysis of 54 epidemiological studies showed that there is a slightly increased relative risk of developing breast cancer diagnosed in women currently taking COCs (relative risk - 1.24). The increased risk gradually disappears within 10 years of stopping these drugs. Because breast cancer is rare in women under 40 years of age, the increase in breast cancer diagnoses in current or recent COC users is small relative to the overall risk of breast cancer. Its connection with COC use has not been proven. The observed increased risk may be a consequence of careful monitoring and earlier diagnosis of breast cancer in women using COCs. Women who have ever used COCs are diagnosed with earlier stages of breast cancer than women who have never used them.
In rare cases, during the use of COCs, the development of benign, and in extremely rare cases, malignant liver tumors, which in some patients led to life-threatening intra-abdominal bleeding, was observed. If severe abdominal pain, liver enlargement, or signs of intra-abdominal bleeding occur, this should be taken into account when making a differential diagnosis.
Other states
Clinical studies have shown no effect of drospirenone on the concentration of potassium in the blood plasma of patients with mild to moderate renal failure. However, in patients with impaired renal function and the initial potassium concentration at ULN, the risk of developing hyperkalemia while taking drugs that lead to potassium retention in the body cannot be excluded.
Women with hypertriglyceridemia (or a family history of this condition) may have an increased risk of developing pancreatitis while taking COCs.
Although slight increases in blood pressure have been described in many women taking COCs, clinically significant increases have rarely been observed. However, if a persistent clinically significant increase in blood pressure develops while taking Jess®Plus, this drug should be discontinued and treatment of arterial hypertension should be started. The drug can be continued if normal blood pressure values are achieved with antihypertensive therapy.
The following conditions have been reported to develop or worsen both during pregnancy and while taking COCs, but their relationship with COC use has not been proven: jaundice and/or pruritus associated with cholestasis; formation of gallstones; porphyria; SLE; hemolytic-uremic syndrome; chorea; herpes during pregnancy; hearing loss associated with otosclerosis.
Cases of worsening the course of endogenous depression, epilepsy, Crohn's disease and ulcerative colitis during the use of COCs have also been described.
In women with hereditary forms of angioedema, exogenous estrogens may cause or worsen symptoms of angioedema.
Acute or chronic liver dysfunction may require discontinuation of Jess®Plus until liver function tests return to normal.
Recurrence of cholestatic jaundice, which developed for the first time during a previous pregnancy or previous use of sex hormones, requires discontinuation of the drug Jess®Plus.
Although COCs may have an effect on insulin resistance and glucose tolerance, there is usually no need to adjust the dose of hypoglycemic drugs in patients with diabetes mellitus using low-dose oral contraceptives (ethinyl estradiol - <0.05 mg). However, women with diabetes mellitus should be carefully monitored while taking COCs.
Chloasma can sometimes develop, especially in women with a history of chloasma during pregnancy. Women with a tendency to chloasma while taking Jess®Plus should avoid prolonged exposure to the sun and exposure to UV radiation.
Folates may mask vitamin B12 deficiency.
Laboratory tests
Taking Jess®Plus may affect the results of some laboratory tests, including indicators of liver, kidney, thyroid, adrenal function, the concentration of transport proteins in plasma, indicators of carbohydrate metabolism, parameters of blood coagulation and fibrinolysis. Changes usually do not go beyond normal values. Drospirenone increases plasma renin activity and aldosterone concentrations, which is associated with its antimineralocorticoid effect.
Reduced efficiency
The contraceptive effectiveness of Jess®Plus may be reduced in the following cases: when pink pills are missed, gastrointestinal disorders while taking pink pills, or as a result of drug interactions.
Frequency and severity of menstrual-like bleeding
While taking the drug Jess®Plus, during the first few months, irregular (acyclic) bleeding from the vagina (spotting and/or breakthrough uterine bleeding) may be observed. You should use hygiene products and continue taking your tablets as usual. Any irregular bleeding should be assessed after an adaptation period of approximately 3 cycles.
If irregular bleeding recurs or develops after previous regular cycles, careful evaluation should be performed to rule out malignancy or pregnancy.
No regular menstrual bleeding
Some women may not develop withdrawal bleeding while taking the light orange booster tablets. If Jess®Plus was taken as recommended, it is unlikely that the woman is pregnant. However, if the Jess®Plus regimen is not followed and there are no withdrawal bleedings in a row, the drug cannot be continued until pregnancy has been ruled out.
Medical examinations
Before starting or resuming use of the drug, it is necessary to familiarize yourself with the woman’s life history, family history, conduct a thorough physical examination (including measuring blood pressure, heart rate, determining BMI, examining the mammary glands), gynecological examination, cytological examination of the cervix (Papanicolaou test), and exclude pregnancy. . When resuming taking the drug Jess®Plus, the volume of additional studies and the frequency of control examinations are determined individually, but at least once every 6 months.
It must be borne in mind that the drug Jess®Plus does not protect against HIV infection and other sexually transmitted diseases.
Conditions requiring medical consultation:
- any changes in health, especially the occurrence of conditions listed in the sections “Contraindications” and Precautions
;
— local compaction in the mammary gland;
- simultaneous use of other medications (see “Interaction”);
- if prolonged immobility is expected (for example, a cast is applied to the lower limb), hospitalization or surgery is planned (at least 4 weeks before the proposed operation);
- unusually heavy bleeding from the vagina;
- missed a pill in the first week of taking the package and had sexual intercourse 7 days or less before;
- absence of regular menstrual-like bleeding 2 times in a row or suspicion of pregnancy (you should not start taking pills from the next package before consulting your doctor).
You should stop taking the tablets and consult your doctor immediately if there are possible signs of thrombosis, myocardial infarction or stroke: unusual cough; unusually severe pain behind the sternum, radiating to the left arm; unexpected shortness of breath, unusual, severe and prolonged headache or migraine attack; partial or complete loss of vision or double vision; slurred speech; sudden changes in hearing, smell, or taste; dizziness or fainting; weakness or loss of sensation in any part of the body; severe abdominal pain; severe pain in the lower limb or sudden swelling of any of the lower limbs.
Impact on the ability to drive vehicles and machinery.
There have been no reported cases of adverse effects of the drug Jess®Plus on the speed of psychomotor reactions; No studies have been conducted to study the effect of the drug on the speed of psychomotor reactions.
Adverse reactions
When using this medication, the following side symptoms may occur:
- headache, migraine;
- dyspepsia;
- soreness of the mammary glands;
- irregular uterine bleeding;
- venous and arterial thromboembolism;
- psychoemotional disorders;
- mood swings;
- change in sexual desire.
As a rule, such negative manifestations can be observed only during the first months of taking the medication, during the period of adaptation of the body to the active substance. If symptoms do not disappear, you should consult a specialist who may prescribe other contraceptive drugs or cancel them due to intolerance.
Analogs of Jess contraceptives give the same side effects.
Analogues of Jess and Jess Plus
Why are you looking for analogues? Perhaps you want to buy the drug cheaper. Or Jess's contraceptives simply weren't right for you. Anyway:
IMPORTANT! Do not change medications yourself. Go to an appointment with a gynecologist and get a consultation. Your doctor should choose the best contraceptive method for you.
Claira and Jess plus / Jess
We are unlikely to be able to help you with the question “what is better” - it is better to consult with a specialist so that he can select a contraceptive that is suitable for you.
What's the difference? Both drugs are microdosed (up to 20 mcg Ethinyl estradiol).
But the active components are different: Jess (Jess plus) – Ethinyl estradiol and Drospirenone; Qlaira – Estradiol valerate and Dienogest.
And the combination of hormones is different: Jess (Jess plus) is a monophasic contraceptive (one combination of hormones for all pills throughout the entire cycle). Qlaira – multiphase (more than three combinations, namely four).
By price: the cost of Klayra is from 1101 (per pack of 28 pieces).
Lindineth or Jess plus / Jess
By composition:
- Lindinet 20 contains per 1 tablet: Ethinyl estradiol 20 mcg and Gestodene 75 mcg.
- Lindinet 30 contains per 1 tablet: Ethinyl estradiol 30 mcg and Gestodene 75 mcg.
The main difference is the second active substance. In Jess and Jess plus it is drospirenone, and in Lindinet it is gestodene.
In Lindinet 30, the dose of ethinyl estradiol is also increased - 30 mcg.
By price:
- A package of Lindinet 20 (21 tablets) - from 400 rubles, a large package (63 tablets) - from 890 rubles.
- A package of Lindinet 30 (21 tablets) – from 500 rubles, a large pack (63 tablets) – from 1230 rubles.
Diana is 35 or Jess plus / Jess
Both drugs are monophasic COCs.
Comparison by composition:
- Diane-35 – Ethinyl estradiol (35 mcg) and Cyproterone acetate (2 mg).
- Jess (Jess plus) – Ethinyl estradiol (20 mcg) and Drospirenone (3 mg).
By price: Diana 35 costs from 1030 rubles (for 21 pieces).
Logest or Jess plus / Jess
The active ingredients in Logest are Ethinyl estradiol and Gestodene, in Jess (Jess plus) - Ethinyl estradiol and Drospirenone.
Logest is a low-dose (up to 30 mcg) monophasic combined oral contraceptive. Jess (Jess plus) – microdosed (up to 20 vru)/
By price: Logest cost – from 837 rubles (pack of 21 pcs.)
Dimia and Jess plus / Jess
Both drugs are monophasic oral contraceptives. Similar in composition:
- Drospirenone – 3 mcg
- Ztinylestradiol – 20 mcg
(We remember that Jess Plus also contains calcium levomefolate.)
By price: cost of Dimia - from 587 rubles (pack of 21 pcs.)
Regulon and Jess plus / Jess
Both contraceptives are monophasic.
There are differences in composition: 1 tablet of Regulon contains Ethinyl estradiol 30 mcg and Desogestrel 15 mcg. Those. differences in dosage and second active substance.
By price: Regulon cost – from 381 rubles (pack of 21 pcs.)
Contraindications
The list of main contraindications to the use of “Jess” includes:
- hypersensitivity to components;
- lactation period;
- benign or malignant tumors in the liver;
- pregnancy or suspicion of it;
- thromboembolism and thrombosis, as well as previous conditions, including history;
- migraine with symptoms of neuralgia;
- diabetes mellitus, which is accompanied by vascular disorders;
- cerebrovascular pathologies;
- hormone-dependent malignancies or suspicion of them;
- severe and acute forms of renal failure;
- pancreatitis with hypertriglyceridemia;
- adrenal insufficiency;
- liver failure and other liver pathologies in severe forms;
- vaginal bleeding of unknown origin.
If pregnancy is detected, the medication is immediately discontinued, but if it was inadvertently used in the early stages of pregnancy, there is no need to worry, this does not carry an increased risk of developmental defects in the fetus. It should also be noted that if one of the side effects is observed for the first time while using the drug, it must be abandoned. Contraceptives "Jess" can be taken for a long time, and there is no age limit.
"Jess" or "Dimia"? Comparison
Both remedies do a good job of their intended purpose - block ovulation, suppress sex hormones, treat gynecological disorders and acne. For therapeutic purposes, oral antiandrogen contraceptives are prescribed for the treatment of alopecia and virilization. "Jess" and the analogue "Dimia" are generics, but they have some differences. Firstly, they are cost and can be purchased for about 1,500 rubles, and the drug “Dimia” - for 800 rubles.
That is, “Dimia” is an analogue of “Jess”, but cheaper. The price differs by a factor of 2, which in some cases plays a significant role in drug preference. Dimiya has a wider list of side effects, which include swelling, headaches, intolerance to contact lenses, cellulite, and weight gain. Therefore, in this case, you should carefully consider the selection of the drug and weigh the benefits and harms of possible negative reactions, taking into account the large difference in price.
You may be interested in:Enterobacter cloacae: decoding, norm and pathology
Let's consider another analogue of "Jess".
Side effects
The side effects of Jess on the body are less pronounced than those of other COCs. To quantify the frequency of side effects, a gradation was used: often - more than 1%, not often - between 1% and 1‰, rarely - less than 1‰. Organs of the gastrointestinal tract (GIT). Common: abdominal pain, nausea; uncommon: stool disorders, vomiting. Nervous system. Often: emotional lability, nervousness, asthenia, headache, infrequently: false migraine, decreased libido, rarely: increased libido. Organs of vision. Rarely: discomfort from wearing contact lenses. Genitourinary system (GUS). Often: intermittent pain in the mammary glands, thrush (candidiasis of the vaginal mucosa), dysmenorrhea, uterine bleeding, infrequently: symmetrical breast enlargement, rarely: discharge from the breast and vagina. Skin. Common: increased oiliness of skin and hair; uncommon: rash; rare: erythema. Other. Often: increase in body mass index, infrequently: pasty legs, rarely: decrease in body mass index, anaphylaxis. In isolated cases, excessive thrombus formation and embolism are possible.
"Jess" or "Yarina"?
Most often, experts recommend the drug "Jess", especially at the beginning of treatment, since it is a gentler drug with fewer side effects, unlike all the others.
The high effectiveness of the analogue of the drug "Jess" "Yarina" in the treatment of acne is associated with a fairly high content of ethinyl estradiol in this product, which provides a more noticeable and faster result. The price of these drugs is almost the same, and the treatment of acne and acne is very effective in both cases. Therefore, it is impossible to say exactly which of these remedies is better, since contraindications, side reactions, and the positive effect of their use are equivalent.
What other analogues in the composition of “Jess” are there?
Interaction with other drugs
Drugs that increase the activity of microsomal enzymes in the liver (phenytoin, barbituric acid derivatives, primidone derivatives, carbamazepine, rifampicin antibiotics and some others) reduce the level of sex hormones in the blood. In case of simultaneous use with Jess, additional contraception is carried out throughout the treatment period and for another 28 days. Penicillins and tetracyclines reduce the level of sex hormones in the blood, so barrier contraception is required while taking them, and in the next week after discontinuation.
"Jess" or "Janine"?
Both medications affect ovulatory functions (prevent ovulation) and, in addition, make the cervical mucus thicker, which is the main obstacle to the penetration of sperm into the uterus.
The therapeutic effect is provided by the gestagenic component of both drugs. While taking these tablets, there is no fluid retention in the body, body weight remains normal. A beneficial effect on lipid metabolism is also recorded. Reviews of the “Jess” analogue confirm this.
When taking hormonal tablets "Janine" it is possible to get rid of alopecia and hirsutism associated with an excess of testosterone. In addition, the contraceptive normalizes the circulatory cycle and relieves painful symptoms during menstruation. The drug is often prescribed for uterine fibroids and endometriosis.
The difference in price between the drugs is insignificant; “Janine” is approximately 500 rubles cheaper than “Jess”. Otherwise, both products are very effective and there are no significant differences between them.
Let's consider what people think about these analogues of “Jess” in composition.
Which drug is better
When choosing a contraceptive (Jess or Yarina, Jess or Dimia, etc.), you should first visit a gynecologist. The specialist prescribes a contraceptive for each woman individually.
Jess analogues have a similar active ingredient and, accordingly, have the same effect on the body.
In this case, the advantage of analogues is their lower price.
When choosing a contraceptive, doctors advise paying attention to the following points:
- Age category of contraceptives.
- A number of side effects.
- Possible contraindications.
